The medical technology developer received series D funding from investors including existing backer Tencent, pushing its total funding past $120m.

China-based gene-sequencing technology developer Vision Medicals has raised RMB300m ($47m) in a series D round featuring internet and gaming group Tencent, DealStreetAsia reported today, citing a company statement.

Private equity firm Boyu Capital also participated in the round, as did CDH Venture and Growth Capital, a vehicle for alternative asset management firm CDH.

Founded in 2018, Vision Medicals is using gene editing technology to create diagnostics tools and therapeutics to treat infectious diseases.

The series D funds will be used…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn